BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37070183)

  • 1. Prescription trends for preservative free glaucoma medication in a public health system.
    Pérez-García P; Burgos-Blasco B; Morales-Fernández L; Fernández-Ruiz-Morón A; Gómez-Calleja V; Oribio-Quinto C; Collado-Vincueria I; Garcia-Feijoo J; Martinez-de-la-Casa JM
    Eur J Ophthalmol; 2024 Jan; 34(1):193-203. PubMed ID: 37070183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
    J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis.
    Hedengran A; Steensberg AT; Virgili G; Azuara-Blanco A; Kolko M
    Br J Ophthalmol; 2020 Nov; 104(11):1512-1518. PubMed ID: 32051133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.
    Nagstrup AH
    Acta Ophthalmol; 2023 Dec; 101 Suppl 278():3-21. PubMed ID: 38037546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.
    El Ameen A; Vandermeer G; Khanna RK; Pisella PJ
    Eur J Ophthalmol; 2019 Nov; 29(6):645-653. PubMed ID: 30301370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases.
    Schwartz GF; Kotak S; Mardekian J; Fain JM
    BMC Ophthalmol; 2011 Jun; 11():14. PubMed ID: 21672240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
    Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
    Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.
    Cucherat M; Stalmans I; Rouland JF
    J Glaucoma; 2014 Jan; 23(1):e69-75. PubMed ID: 23881267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
    Aptel F; Choudhry R; Stalmans I
    Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
    Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
    Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.
    Holló G; Katsanos A; Boboridis KG; Irkec M; Konstas AGP
    Drugs; 2018 Jan; 78(1):39-64. PubMed ID: 29196953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients.
    Kestelyn PA; Kestelyn PG; De Bacquer D; Stevens AM
    Int Ophthalmol; 2019 Jan; 39(1):105-109. PubMed ID: 29274019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
    Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
    J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.
    DuBiner HB; Hubatsch DA
    BMC Ophthalmol; 2014 Nov; 14():151. PubMed ID: 25432143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of preserved versus preservative-free beta-blockers in patients with glaucoma or ocular hypertension: a systematic review.
    Skov AG; Rives AS; Freiberg J; Virgili G; Azuara-Blanco A; Kolko M
    Acta Ophthalmol; 2022 May; 100(3):253-261. PubMed ID: 34128326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
    Lopes JF; Hubatsch DA; Amaris P
    BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preservatives in glaucoma medication.
    Steven DW; Alaghband P; Lim KS
    Br J Ophthalmol; 2018 Nov; 102(11):1497-1503. PubMed ID: 29973365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.